I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease

Neurochemistry International

Volumn 30, Issue 1, 1997, Pages 31-36

  Gargalidis Moudanos, C ^a   Pizzinat, N ^a   Javoy Agid, F ^b   Remaury, A ^a   Parini, A ^a  

^a CHU RANGUEIL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CARBON 14; IDAZOXAN; IMIDAZOLINE; PHENETHYLAMINE; RADIOLIGAND; TYRAMINE; DRUG RECEPTOR; IMIDAZOLINE RECEPTORS; PHENETHYLAMINE DERIVATIVE; TRITIUM;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN CORTEX; BRAIN MITOCHONDRION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; NERVE DEGENERATION; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; BRAIN; CADAVER; METABOLISM; MITOCHONDRION; ULTRASTRUCTURE;

AGED; AGED, 80 AND OVER; BRAIN; CEREBRAL CORTEX; FEMALE; HUMANS; IDAZOXAN; MALE; MITOCHONDRIA; MONOAMINE OXIDASE; PARKINSON DISEASE; PHENETHYLAMINES; POSTMORTEM CHANGES; PUTAMEN; RECEPTORS, DRUG; TRITIUM; TYRAMINE;

EID: 0030614877     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(96)00035-6     Document Type: Article

References (30)

1. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of protein utilizing the principle protein-dye binding. Analyt. Biochem. 72, 248-252.
2. 3H]idazoxan in the human cerebral cortex. Neurochem. Int. 22, 153-163.
3. 2 sites. J. Pharmacol. Exp. Ther. 272, 681-688.
4. Coupry, I., Atlas, D., Podevin, R. A., Uzielli, I. and Parini, A. (1989) Imidazoline-guanidinium receptive site in renal proximal tubule: asymetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. J. Pharmacol. Exp. Ther. 252, 293-299.
5. 3H]rauwolscine. Brain Res. 566, 13-20.
6. Diamant, S., Eldar-Geva, T. and Atlas, D. (1992) Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. Br. J. Pharmacol. 106, 101-108.
7. Escriba, P. V., Sastre, M., Wang, H., Regunathan, S., Reis, D. J. and Garcia-Sevilla, J. A. (1994) Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci. Lett. 178, 81-84.
8. Gerlach, M., Riederer, P., Przuntek, H. and Youdim, B. H. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208, 273-286.
9. Girmen, A. S., Baenziger, J., Hotamisligil, G. S., Konradi, C., Shalish, C., Sullivan, J. L. and Breakefield, X. O. (1992) Relationship between platelet monoamine oxidase B activity and alleles at the MAOB locus. J. Neurochem. 59, 2063-2066.
10. Heinonen, E. H. and Lammintausta, R. (1991) A review of the pharmacology of selegiline. Acta Neurol. Scand. 84, 44-59.
11. Ho, S. L., Kapadi, A. L., Ramsden, D. B. and Williams, A. C. (1995) An allelic association study of monoamine oxidase B in Parkinson's disease. Ann. Neurol. 37, 403-405.
12. Hotamisligil, G. S., Girmen, A. S., Fink, J. S., Tivol, E., Shalish, C., Trofatter, J., Baenziger, J., Diamond, S., Markham, C., Sullivan, J., Growdon, J. and Breakefield, X. O. (1994) Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Movement Disord. 9, 305-310.
13. 2-adrenoceptors and non-adrenoceptor imidazoline binding sites in the central nervous system. Br. J. Pharmacol. 109, 831-837.
14. Kopin, I. J. (1993) The pharmacology of Parkinson's disease therapy: an update. Annu. Rev. Pharmacol. Toxicol. 32, 467-495.
15. Kurth, J. H., Kurth, M.C., Poduslo, S. E. and Schwankhaus, J. D. (1993) Association of a monoamine oxidase B allele with Parkinson's disease. Ann. Neurol. 33, 368-372.
16. Mattammal, M. B., Chung, H. D., Strong, R. and Hsu, F. F. (1993) Confirmation of a dopamine metabolite in Parkinsonian brain tissue by gas chromatography-mass spectrometry. J. Chromatogr. 614, 20-212.
17. 3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol. Psychiatry 34, 498-501.
18. 3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J. Pharmacol. Exp. Ther. 264, 1187-1197.
19. Naoi, M. and Maruyama, W. (1993) Type B monoamine oxidase and neurotoxins. Eur. Neurol. 33, 31-37.
20. Parini, A., Gargalidis-Moudanos, C., Pizzinat, N. and Lanier, S. M. (1996) Defining the eclectic family of imidazoline binding sites. Trends Pharmacol. Sci. 17, 0-0.
21. Raddatz, R., Parini, A. and Lanier, S. M. (1995) Imidazoline/Guanidinium binding domains on monoamine oxidases: Relatioship to subtypes of imidazoline binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J. Biol. Chem. 270 (46), 27961-27968.
22. 2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci. Lett. 160, 109-112.
23. 2 with monoamine oxidase-B sites. J. Neurochem. 61, 881-889.
24. 3H-Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs and human brain. J. Neurosci. 12, 1977-1999.
25. Tesson, F., Prip-Buus, C., Lemoine, A., Pegorier, J. P. and Parini, A. (1991) Subcellular distribution of imidazoline-guanidinium receptive sites in human and rabbit liver. J. Biol. Chem. 266, 155-160.
26. Tesson, F., Limon, I. and Parini, A. (1992) Tissue specific localization of mitochondrial imidazoline-guanidinium receptive sites. Eur. J. Pharmacol. 219, 335-338.
27. 2-imidazoline binding sites on monoamine oxidases. J. Biol. Chem. 270, 9856-9861.
28. Yasuhara, H., Parvez, S. H., Oguchi, K., Sandler, M. and Nagatsu, T., Eds (1993) Monoamine oxidase: Basic and Clinical Aspects. VSP, Utrecht, The Netherlands.
29. Wang, H., Regunathan, S., Ruggiero, D. A. and Reis, D. J. (1993) Production and characterization of antibodies specific for the imidazoline receptor protein. Mol. Pharmacol. 43, 509-515.
30. Wessel, K. and Szelenyi, I. (1992) Selegiline - an overview of its role in the treatment of Parkinson's disease. Clin. Invest. 70, 459-162.